Tags

Type your tag names separated by a space and hit enter

Shockwave Therapy in the Treatment of Peyronie's Disease.
Sex Med Rev. 2019 07; 7(3):499-507.SM

Abstract

INTRODUCTION

Peyronie's disease is an acquired condition of the connective tissue of the penis that affects 0.5-20.3% of the male population and is marked by fibrotic plaques in the tunica albuginea. It can result in penile curvature/deviation, painful erections, and sexual dysfunction. Several treatment modalities have been proposed, with studies from the past decade investigating extracorporeal shockwave therapy's (ESWT) potential efficacy in Peyronie's management.

AIMS

To investigate the effects of ESWT on Peyronie's disease parameters such as penile curvature, plaque size, erectile function, and penile pain.

METHODS

We reviewed the literature examining the effects of ESWT on Peyronie's disease.

MAIN OUTCOME MEASURES

The main outcome measures after receiving extracoporeal shockwave therapy included changes in degree of penile curvature, penile plaque size, International Index of Erectile Function-5 questionnaire score, and visual analogue scale score.

RESULTS

Randomized controlled trials examining the efficacy of ESWT in Peyronie's disease do not show a statistically significant benefit in curvature reduction, plaque size, or erectile function, although a recent meta-analysis demonstrates a benefit in plaque size reduction. A statistically significant reduction in penile pain has been observed across multiple studies.

CONCLUSION

Extracorporeal shockwave therapy may be beneficial in the management of Peyronie's disease for refractory penile pain and plaque size reduction. However, penile pain typically resolves spontaneously over time, and shockwave therapy can pose a substantial financial burden to patients. A multi-institutional randomized controlled trial with standardization of methods and strict inclusion criteria regarding disease duration would prove beneficial in determining the true efficacy of shockwave therapy in Peyronie's disease. Krieger JR, Rizk PJ, Kohn TP, et al. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev 2019;7:499-507.

Authors+Show Affiliations

Department of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.Department of Urology, University of Miami, Miami, FL, USA.Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.Division of Urology, Department of Surgery, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: alexander.pastuszak@hsc.utah.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30926460

Citation

Krieger, Jordan R., et al. "Shockwave Therapy in the Treatment of Peyronie's Disease." Sexual Medicine Reviews, vol. 7, no. 3, 2019, pp. 499-507.
Krieger JR, Rizk PJ, Kohn TP, et al. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev. 2019;7(3):499-507.
Krieger, J. R., Rizk, P. J., Kohn, T. P., & Pastuszak, A. (2019). Shockwave Therapy in the Treatment of Peyronie's Disease. Sexual Medicine Reviews, 7(3), 499-507. https://doi.org/10.1016/j.sxmr.2019.02.001
Krieger JR, et al. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev. 2019;7(3):499-507. PubMed PMID: 30926460.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Shockwave Therapy in the Treatment of Peyronie's Disease. AU - Krieger,Jordan R, AU - Rizk,Paul J, AU - Kohn,Taylor P, AU - Pastuszak,Alexander, Y1 - 2019/03/26/ PY - 2018/12/12/received PY - 2019/01/28/revised PY - 2019/02/04/accepted PY - 2019/3/31/pubmed PY - 2020/5/6/medline PY - 2019/3/31/entrez KW - Erectile Dysfunction KW - Penile Curvature KW - Penile Pain KW - Peyronie’s Disease KW - Plaque KW - Shockwave Therapy SP - 499 EP - 507 JF - Sexual medicine reviews JO - Sex Med Rev VL - 7 IS - 3 N2 - INTRODUCTION: Peyronie's disease is an acquired condition of the connective tissue of the penis that affects 0.5-20.3% of the male population and is marked by fibrotic plaques in the tunica albuginea. It can result in penile curvature/deviation, painful erections, and sexual dysfunction. Several treatment modalities have been proposed, with studies from the past decade investigating extracorporeal shockwave therapy's (ESWT) potential efficacy in Peyronie's management. AIMS: To investigate the effects of ESWT on Peyronie's disease parameters such as penile curvature, plaque size, erectile function, and penile pain. METHODS: We reviewed the literature examining the effects of ESWT on Peyronie's disease. MAIN OUTCOME MEASURES: The main outcome measures after receiving extracoporeal shockwave therapy included changes in degree of penile curvature, penile plaque size, International Index of Erectile Function-5 questionnaire score, and visual analogue scale score. RESULTS: Randomized controlled trials examining the efficacy of ESWT in Peyronie's disease do not show a statistically significant benefit in curvature reduction, plaque size, or erectile function, although a recent meta-analysis demonstrates a benefit in plaque size reduction. A statistically significant reduction in penile pain has been observed across multiple studies. CONCLUSION: Extracorporeal shockwave therapy may be beneficial in the management of Peyronie's disease for refractory penile pain and plaque size reduction. However, penile pain typically resolves spontaneously over time, and shockwave therapy can pose a substantial financial burden to patients. A multi-institutional randomized controlled trial with standardization of methods and strict inclusion criteria regarding disease duration would prove beneficial in determining the true efficacy of shockwave therapy in Peyronie's disease. Krieger JR, Rizk PJ, Kohn TP, et al. Shockwave Therapy in the Treatment of Peyronie's Disease. Sex Med Rev 2019;7:499-507. SN - 2050-0521 UR - https://wwww.unboundmedicine.com/medline/citation/30926460/Shockwave_Therapy_in_the_Treatment_of_Peyronie's_Disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2050-0521(19)30007-1 DB - PRIME DP - Unbound Medicine ER -